Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?

@article{Wit2005IsTA,
  title={Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?},
  author={R. de Wit and M. Aapro and P. Blower},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2005},
  volume={56},
  pages={231-238}
}
  • R. de Wit, M. Aapro, P. Blower
  • Published 2005
  • Medicine
  • Cancer Chemotherapy and Pharmacology
  • Abstract5-HT3-receptor antagonists are the current antiemetic ‘gold standard’ for chemotherapy- and radiotherapy-induced nausea and vomiting. Interestingly, studies have shown that patients experiencing poor control of acute chemotherapy-induced nausea and vomiting with one antiemetic therapy may respond well to another agent, including a drug of the same class. This review examines pharmacological differences between the 5-HT3-receptor antagonists in order to determine potential reasons for… CONTINUE READING
    38 Citations

    Figures, Tables, and Topics from this paper.

    Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists
    • 12
    • PDF
    Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics
    • 50
    • PDF
    Therapeutics of 5-HT3 receptor antagonists: current uses and future directions.
    • T. Machu
    • Chemistry, Medicine
    • Pharmacology & therapeutics
    • 2011
    • 59
    Evolving treatment paradigms for chemotherapy-induced nausea and vomiting.
    • R. Wickham
    • Medicine
    • Cancer control : journal of the Moffitt Cancer Center
    • 2012
    • 15
    • PDF
    5-hydroxytryptamine and the gastrointestinal tract: where next?
    • G. Sanger
    • Medicine
    • Trends in pharmacological sciences
    • 2008
    • 64
    Treatment of nausea and vomiting: Gaps in our knowledge
    • 175

    References

    SHOWING 1-10 OF 70 REFERENCES
    5‐HT3‐Receptor Antagonists and the Cytochrome P450 System: Clinical Implications
    • 59
    Volunteer models for predicting antiemetic activity of 5-HT3-receptor antagonists.
    • N. Minton
    • Medicine
    • British journal of clinical pharmacology
    • 1994
    • 20
    Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis.
    • C. Lindley, P. Blower
    • Medicine
    • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
    • 2000
    • 34
    • PDF
    Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.
    • 233
    Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics
    • R. de Wit
    • Medicine
    • British journal of cancer
    • 2003
    • 12
    Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
    • 84
    A meta-analysis comparing the efficacy of five 5-HT3-receptor antagonists (5-HT3-RAs) for acute chemotherapy induced emesis.
    • 6